Takeda Pharmaceutical (NYSE:TAK) Rating Lowered to Hold at Zacks Investment Research
According to Zacks, “Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda’s core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide acetate for the treatment of prostate cancer and endometriosis, pioglitazone hydrocholoride for the treatment of diabetes, and candesartan cilexetil for the treatment of hypertension. The Company promotes enhancing R&D pipeline, while concentrating its management resources to the four core therapeutic areas: lifestyle-related diseases, oncology and urological diseases, central nervous system disease and gastroenterological diseases. It operates in two segments- Ethical drug business and Consumer healthcare business. Consumer healthcare business provides Alinamin (vitamin B1 derivative preparations, etc.), Benza (cold remedies). Takeda Pharmaceutical Company Limited is headquartered in Osaka, Japan. “
A number of other brokerages have also weighed in on TAK. ValuEngine upgraded Takeda Pharmaceutical from a strong sell rating to a sell rating in a research report on Thursday, May 14th. JPMorgan Chase & Co. lowered their target price on Takeda Pharmaceutical from $31.00 to $30.00 and set an overweight rating for the company in a research note on Wednesday, March 11th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus price target of $23.50.
Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings data on Wednesday, May 13th. The company reported $0.13 earnings per share for the quarter. The firm had revenue of $7.09 billion for the quarter. Takeda Pharmaceutical had a return on equity of 13.80% and a net margin of 1.37%. As a group, equities research analysts forecast that Takeda Pharmaceutical will post 2.04 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. lifted its stake in shares of Takeda Pharmaceutical by 191.3% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 1,847 shares of the company’s stock valued at $28,000 after purchasing an additional 1,213 shares during the period. American Research & Management Co. lifted its stake in shares of Takeda Pharmaceutical by 3,233.3% in the 1st quarter. American Research & Management Co. now owns 2,000 shares of the company’s stock valued at $30,000 after purchasing an additional 1,940 shares during the period. Private Capital Group LLC raised its stake in Takeda Pharmaceutical by 57.8% during the first quarter. Private Capital Group LLC now owns 2,900 shares of the company’s stock valued at $44,000 after buying an additional 1,062 shares during the last quarter. Ellevest Inc. raised its stake in Takeda Pharmaceutical by 96.2% during the first quarter. Ellevest Inc. now owns 3,184 shares of the company’s stock valued at $48,000 after buying an additional 1,561 shares during the last quarter. Finally, Sunbelt Securities Inc. purchased a new position in Takeda Pharmaceutical during the fourth quarter valued at $16,259,000. Institutional investors own 3.67% of the company’s stock.
Takeda Pharmaceutical Company Profile
Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.
Read More: What is the FTSE 100 index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.